{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AIDSVAX+B%2FE", "query": { "intervention": "AIDSVAX B/E" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 7, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-08T11:30:35.123Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02771730", "title": "Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer", "HIV Vaccine" ], "interventions": [ { "name": "Ad4-mgag", "type": "BIOLOGICAL" }, { "name": "Ad4-EnvC150", "type": "BIOLOGICAL" }, { "name": "Placebo Comparator", "type": "OTHER" }, { "name": "AIDSVAX B/E", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Emergent BioSolutions", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 20, "start_date": "2015-03", "completion_date": "2017-02", "has_results": false, "last_update_posted_date": "2024-03-18", "last_synced_at": "2026-09-08T11:30:35.123Z", "location_count": 1, "location_summary": "Redwood City, California", "locations": [ { "city": "Redwood City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02771730" }, { "nct_id": "NCT00076063", "title": "A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "ALVAC-HIV (vCP1452)", "type": "BIOLOGICAL" }, { "name": "LIPO-5", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 174, "start_date": "2004-03", "completion_date": "2007-03", "has_results": false, "last_update_posted_date": "2021-10-14", "last_synced_at": "2026-09-08T11:30:35.123Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00076063" }, { "nct_id": "NCT03618056", "title": "Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections", "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "AIDSVAX® B/E", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 1, "start_date": "2018-12-19", "completion_date": "2020-07-17", "has_results": true, "last_update_posted_date": "2022-02-07", "last_synced_at": "2026-09-08T11:30:35.123Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03618056" }, { "nct_id": "NCT02207920", "title": "Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "AIDSVAX B/E Vaccine", "type": "BIOLOGICAL" }, { "name": "DNA-HIV-PT123 Vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo for DNA-HIV-PT123", "type": "BIOLOGICAL" }, { "name": "Placebo for AIDSVAX B/E", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 104, "start_date": "2014-07", "completion_date": "2015-12", "has_results": false, "last_update_posted_date": "2021-10-15", "last_synced_at": "2026-09-08T11:30:35.123Z", "location_count": 7, "location_summary": "San Francisco, California • New York, New York • Rochester, New York + 3 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Rochester", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02207920" }, { "nct_id": "NCT00002402", "title": "A Study of AIDSVAX B/B and AIDSVAX B/E, Two Possible Vaccines", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "MN rgp120/HIV-1 and GNE8 rgp120/HIV-1", "type": "BIOLOGICAL" }, { "name": "MN rgp120/HIV-1 and A244 rgp120/HIV-1", "type": "BIOLOGICAL" }, { "name": "Aluminum hydroxide", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "VaxGen", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-09-08T11:30:35.123Z", "location_count": 4, "location_summary": "Denver, Colorado • Washington D.C., District of Columbia • Boston, Massachusetts + 1 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002402" }, { "nct_id": "NCT02852005", "title": "Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "MVA/HIV62B vaccine", "type": "BIOLOGICAL" }, { "name": "AIDSVAX B/E vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 27, "start_date": "2017-01", "completion_date": "2019-10-29", "has_results": true, "last_update_posted_date": "2022-08-08", "last_synced_at": "2026-09-08T11:30:35.123Z", "location_count": 7, "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02852005" }, { "nct_id": "NCT00001096", "title": "A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "MN rgp120/HIV-1 and A244 rgp120/HIV-1", "type": "BIOLOGICAL" }, { "name": "QS-21", "type": "BIOLOGICAL" }, { "name": "rgp120/HIV-1MN", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 60, "start_date": null, "completion_date": "2000-03", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-09-08T11:30:35.123Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Rochester, New York • Nashville, Tennessee + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Rochester", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001096" } ] }